ArticleVascular investigation and therapy
Recent Innovations and Advances in Arteriovenous Fistula Creation: A Narrative Review.
Article in Vascular investigation and therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Acute Thrombosis to Eccentric Neointima in Arteriovenous Fistula.Seminars in thrombosis and hemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Arteriovenous fistulae (AVF) are the gold standard for vascular access among patients requiring hemodialysis; however, AVF have high primary failure rates. Novel approaches and technologies to improve AVF patency include modifications to open approaches, such as the radial artery deviation and reimplantation fistula, and percutaneous approaches, such as the endovascular AVF. Despite these advances, these modifications are limited in reducing neointimal hyperplasia, stenosis, or thrombosis, and thus have limited capacity to improve AVF maturation and utilization; as such, vascular access requires continued innovation. Emerging strategies to prevent neointimal hyperplasia include drug-embedded and bioresorbable perivascular wraps. Increased rates of AVF failure among women highlight sex differences in the biology of AVF maturation and suggest additional targets to improve outcomes. Other advances in understanding the biology of AVF maturation suggest potentialized approaches for patients, including immune system modulation and stem cell therapies. Although these emerging technologies may improve AVF maturation and utilization, longer-term patency and freedom from complications such as central vein stenosis and dialysis access associated distal ischemia emphasize the critical need for continued scientific inquiry and technological development to optimize vascular access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.